Abstract
A case of BCG‐induced granulomatous hepatitis, which developed 1 1/2 years after BCG immunotherapy for recurrent malignant melanoma, is described to document the development of this disease entity as a potential late complication of BCG immunotherapy. The clinical implications of the late development of BCG‐induced granulomatous hepatitis, use of immunosuppressive chemotherapy, and possible alternatives for BCG in intratumor immunotherapy are discussed. Copyright © 1980 American Cancer Society
Cite
CITATION STYLE
Flippin, T., Mukherji, B., & Dayal, Y. (1980). Granulomatous hepatitis as a late complication of BCG immunotherapy. Cancer, 46(8), 1759–1762. https://doi.org/10.1002/1097-0142(19801015)46:8<1759::AID-CNCR2820460810>3.0.CO;2-6
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
